[go: up one dir, main page]

WO2004044154A3 - Methods of identifying antineoplastic agents - Google Patents

Methods of identifying antineoplastic agents Download PDF

Info

Publication number
WO2004044154A3
WO2004044154A3 PCT/US2003/035688 US0335688W WO2004044154A3 WO 2004044154 A3 WO2004044154 A3 WO 2004044154A3 US 0335688 W US0335688 W US 0335688W WO 2004044154 A3 WO2004044154 A3 WO 2004044154A3
Authority
WO
WIPO (PCT)
Prior art keywords
antineoplastic agents
methods
genes
expression
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/035688
Other languages
French (fr)
Other versions
WO2004044154A2 (en
Inventor
Christie Fanton
Mary Lee Mackichan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Priority to AU2003291398A priority Critical patent/AU2003291398A1/en
Publication of WO2004044154A2 publication Critical patent/WO2004044154A2/en
Anticipated expiration legal-status Critical
Publication of WO2004044154A3 publication Critical patent/WO2004044154A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The expression of particular genes is altered in response to treatment of cancer cells with a DNA damaging agent and a Chk1 inhibitor. Expression of such genes, termed 'surrogate marker genes,' can be used to identify test compounds as potential antineoplastic agents, to assess the potential in vivo efficacy of such agents, and to monitor clinical efficacy of treatment with Chk1 inhibitors.
PCT/US2003/035688 2002-11-07 2003-11-07 Methods of identifying antineoplastic agents Ceased WO2004044154A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003291398A AU2003291398A1 (en) 2002-11-07 2003-11-07 Methods of identifying antineoplastic agents

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US42607402P 2002-11-07 2002-11-07
US60/426,074 2002-11-07
US48722803P 2003-07-16 2003-07-16
US60/487,228 2003-07-16
US51673803P 2003-11-04 2003-11-04
US60/516,738 2003-11-04

Publications (2)

Publication Number Publication Date
WO2004044154A2 WO2004044154A2 (en) 2004-05-27
WO2004044154A3 true WO2004044154A3 (en) 2005-12-29

Family

ID=32314892

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/035688 Ceased WO2004044154A2 (en) 2002-11-07 2003-11-07 Methods of identifying antineoplastic agents

Country Status (2)

Country Link
AU (1) AU2003291398A1 (en)
WO (1) WO2004044154A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009099601A2 (en) * 2008-02-04 2009-08-13 Dana-Farber Cancer Institute, Inc. Chk1 suppresses a caspase-2 apoptotic response to dna damage that bypasses p53, bcl-2 and caspase-3
EP2309273B1 (en) * 2009-09-16 2016-05-18 ZEILLINGER, Robert Novel tumor marker determination

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830648A (en) * 1995-05-05 1998-11-03 Sugen, Inc. Assay and method for transcript imaging

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830648A (en) * 1995-05-05 1998-11-03 Sugen, Inc. Assay and method for transcript imaging

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GENG Y. ET AL: "Expression of cyclins E1 and E2 during mouse development and in neoplasia", PNAS, vol. 98, no. 23, 6 November 2001 (2001-11-06), pages 13138 - 13143, XP002992701 *
GUDAS J.M. ET AL: "Cyclin E2, a Novel G1 Cycline That Binds Cdk2 and Is Aberrantly Expressed in Human Cancers", MOLECULAR AND CELLULAR BIOLOGY, vol. 19, no. 1, January 1999 (1999-01-01), pages 612 - 622, XP002109552 *

Also Published As

Publication number Publication date
AU2003291398A1 (en) 2004-06-03
WO2004044154A2 (en) 2004-05-27

Similar Documents

Publication Publication Date Title
WO2004103959A3 (en) Heterocyclic compounds and uses thereof
WO2009043159A8 (en) Neural tumor stem cells and methods of use thereof
NZ593388A (en) Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1) pathway
WO2001089584A3 (en) Contrast agents
WO2003087367A3 (en) Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye
PL375877A1 (en) Hydantoine derivatives and their use as tace inhibitors
WO2004032621A3 (en) Techniques for identifying molecular structures and treating cell types lining a body lumen using fluorescence
ATE526029T1 (en) MEDICAL USE OF A HISTONE DEACETYLASE INHIBITOR AND METHOD FOR ASSESSING ITS ANTI-TUMORAL EFFECT
EP2377528A3 (en) Fatty acid metabolism inhibitors for use in the treatment of cancer
WO2006078287A3 (en) Pde4b inhibitors and uses therefor
WO2005082341A3 (en) NON-PEPTIDYL AGENTS WITH pHSP20-LIKE ACTIVITY, AND USES THEREOF
WO2004000094A3 (en) Predictive markers in cancer therapy
WO2004044168A3 (en) Genetically encoded fluorescent reporters of kinase, methyltransferase, and acetyl-transferase activities
WO2003038129A3 (en) Methods for assessing and treating leukemia
ATE292677T1 (en) COMPOSITIONS AND METHODS FOR INHIBITING CELLULAR G2 TRANSITION AND SENSITIZING CELLS TO DNA-DAMAGEING AGENTS
WO2004028548A3 (en) Inhibitors of the nitrix oxide synthase iii (nos iii) as neuroprotective agents
WO2004063340A3 (en) Methods and compositions for treating cardiovascular disease using 1722, 10280, 59917, 85553, 10653, 9235, 21668, 17794, 2210, 6169, 10102, 21061,17662,1468,12282, 6350, 9035,1820, 23652, 7301, 8925, 8701, 3533, 9462, 9123,12788,17729, 65552,1261, 21476, 33770, 9380, 2569654, 33556, 53656, 44143, 32612, 10671, 261, 44570, 4
WO2003012051A8 (en) Inhibitor of dna methylation
WO2004044154A3 (en) Methods of identifying antineoplastic agents
NO20044321L (en) Piperazinyl or piperidinylamine sulfamic acid amides as inhibitors of steroid sulfatase
WO2004016768A3 (en) Compositions and methods for inferring ancestry
WO2004080273A3 (en) Compositions and methods for diagnosing and treating prostate cancer
GB2431347A (en) Peripherally-acting vasodilators
AU2003295423A1 (en) Novel pharmacophore for the discovery and testing of na, k-atpase inhibitor compositions and methods for their use in treating cardiovascular diseases and conditions
WO2004001027A8 (en) Oligonucleotide inhibitors of mbd2/dna demethylase and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP